NDI Guidance Could Drive Amarin's Gambit To Block Some Omega-3 Imports

Amarin's argument would swing on a finding by FDA that synthetics of omega-3s are not dietary ingredients. With such an FDA determination, a fair trade complaint to International Trade Commission about imports of omega-3 ingredients similar to the active ingredient in Amarin's Rx Vascepa theoretically would not be asking ITC to interpret FDA regulations by investigating imports of substances which FDA has not identified as noncompliant with its regulations.

Amarin Corp. PLC says its options following the failure of fair trade complaint against imports of some omega-3 imports include trying again by arguing that synthetic omega-3s are not dietary ingredients.

That argument, says Amarin General Counsel Joseph Kennedy, would swing on a finding by the US Food and Drug Administration...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation